Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing “wax-and-wane” transformation

Table 1 Small-cell lung cancer with EGFR mutations and treatment outcomes

Prior TKI	Mutation	Chemotherapy	PFS	Hist after Tx	Ref.
None	L861Q	CDDP + CPT-11	7 mo	Adenocarcinoma	*
E	L861Q	AMR	8 mo	N/A	*
None	G719A	G	N/A (PR)	N/A	[9]
None	Ex19del	CRT	7 mo	N/A	[10]
None	Ex19del	CDDP + VP-16	6 mo	N/A	[10]
G	Ex19del	G	5 mo	N/A	[18]
G, E	Ex19del	G + VP-16	N/A (PD)	N/A	[12]
G	Ex19del	CDDP + CPT-11	6 mo	Adenocarcinoma	[11]
G, E	L858R	TOP	>4 mo (CR)	N/A	[13]
E	L858R	CRT	6 mo	Adenocarcinoma	[8]
E	L858R	CDDP + VP-16	N/A (PR)	N/A	[8]
G	L858R	CDDP + VP-16	N/A (PR)	N/A	[14]

Reports without sufficient information about treatment are not included on this table.
*, present case; AMR, Amrubicin; CDDP, Cisplatin; CPT-11, Irinotecan; CR, Complete response; CRT, Combined chemoradiotherapy; E, Erlotinib; Ex19del, Exon 19 deletions; G, Gefitinib; Hist after Tx, Histology after treatment; mo, Months; N/A, Not assessed; PFS, Progression-free survival; PR, Partial response; Ref., Reference; TKI, Epidermal growth factor receptor tyrosine kinase inhibitor; TOP, Topotecan; VP-16, Etoposide.

ISSN: 1471-2407